$BLUE
bluebird bio, Inc. Stock $blue

$blue Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000129397121000065 Filed on August 09, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$143.0K	$0.00
YoY Change		-100.0%
Cost Of Revenue	$15.22M	$1.554M
YoY Change	879.09%	153.51%
Gross Profit	-$15.07M	-$1.554M
YoY Change	869.88%	-112.25%
Gross Profit Margin	-10539.86%
Selling, General & Admin	$54.98M	$68.63M
YoY Change	-19.88%	0.0%
% of Gross Profit
Research & Development	$84.65M	$156.3M
YoY Change	-45.85%	6.67%
% of Gross Profit
Depreciation & Amortization	$5.993M	$4.550M
YoY Change	31.71%	12.35%
% of Gross Profit
Operating Expenses	$139.6M	$224.9M
YoY Change	-37.93%	4.54%
Operating Profit	-$154.7M	-$143.7M
YoY Change	7.69%	-29.13%
Interest Expense	$218.0K	$2.939M
YoY Change	-92.58%	-68.69%
% of Operating Profit
Other Income/Expense, Net	-$1.274M	$1.551M
YoY Change	-182.14%	-152.83%
Pretax Income	-$155.8M	-$21.46M
YoY Change	625.97%	-89.07%
Income Tax	$216.0K	$10.00K
% Of Pretax Income
Net Earnings	-$241.7M	-$21.47M
YoY Change	1026.03%	-89.04%
Net Earnings / Revenue	-169022.38%
Basic Earnings Per Share	-$3.58	-$0.36
Diluted Earnings Per Share	-$3.58	-$0.36
COMMON SHARES
Basic Shares Outstanding	67.49M shares	60.38M shares
Diluted Shares Outstanding	67.49M shares	60.38M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$941.6M	$1.599B
YoY Change	-41.1%	3.7%
Cash & Equivalents	$353.5M	$1.199B
Short-Term Investments	$588.2M	$400.0M
Other Short-Term Assets	$50.32M	$60.10M
YoY Change	-16.27%	65.11%
Inventory	$13.50M
Prepaid Expenses	$33.73M	$39.36M
Receivables	$0.00	$4.000M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$903.5M	$1.613B
YoY Change	-44.0%	24.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$158.8M	$155.4M
YoY Change	2.22%	20.32%
Goodwill	$13.13M	$13.13M
YoY Change	0.0%	0.0%
Intangibles	$16.26M	$12.18M
YoY Change	33.49%	-26.07%
Long-Term Investments	$101.9M	$49.40M
YoY Change	106.33%	-82.84%
Other Assets	$69.80M	$74.78M
YoY Change	-6.66%	-11.94%
Total Long-Term Assets	$550.9M	$494.3M
YoY Change	11.45%	-31.58%
TOTAL ASSETS
Total Short-Term Assets	$903.5M	$1.613B
Total Long-Term Assets	$550.9M	$494.3M
Total Assets	$1.454B	$2.108B
YoY Change	-31.0%	4.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$39.29M	$26.18M
YoY Change	50.09%	-11.12%
Accrued Expenses	$168.8M	$125.9M
YoY Change	34.08%	44.22%
Deferred Revenue	$2.687M	$3.915M
YoY Change	-31.37%	-58.72%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$247.8M	$197.2M
YoY Change	25.65%	21.63%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.891M	$4.335M
YoY Change	82.03%	155.15%
Total Long-Term Liabilities	$7.891M	$4.335M
YoY Change	82.03%	155.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$247.8M	$197.2M
Total Long-Term Liabilities	$7.891M	$4.335M
Total Liabilities	$469.9M	$425.8M
YoY Change	10.37%	10.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.350B	-$2.506B
YoY Change	33.68%	35.27%
Common Stock	$676.0K	$662.0K
YoY Change	2.11%	19.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$984.6M	$1.682B
YoY Change
Total Liabilities & Shareholders Equity	$1.454B	$2.108B
YoY Change	-31.0%	4.17%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$241.7M	-$21.47M
YoY Change	1026.03%	-89.04%
Depreciation, Depletion And Amortization	$5.993M	$4.550M
YoY Change	31.71%	12.35%
Cash From Operating Activities	-$145.6M	$39.74M
YoY Change	-466.49%	-128.82%
INVESTING ACTIVITIES
Capital Expenditures	-$3.574M	-$4.800M
YoY Change	-25.54%	-74.21%
Acquisitions
YoY Change
Other Investing Activities	$63.94M	$274.1M
YoY Change	-76.67%	9.18%
Cash From Investing Activities	$60.37M	$269.3M
YoY Change	-77.58%	15.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$541.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	392.0K	543.1M
YoY Change	-99.93%	11262.55%
NET CHANGE
Cash From Operating Activities	-145.6M	39.74M
Cash From Investing Activities	60.37M	269.3M
Cash From Financing Activities	392.0K	543.1M
Net Change In Cash	-84.88M	852.1M
YoY Change	-109.96%	757.97%
FREE CASH FLOW
Cash From Operating Activities	-$145.6M	$39.74M
Capital Expenditures	-$3.574M	-$4.800M
Free Cash Flow	-$142.1M	$44.54M
YoY Change	-418.97%	-137.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001293971
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Registrant Name EntityRegistrantName	bluebird bio, Inc.
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35966
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	13-3680878
	dei	Entity Address Address Line1 EntityAddressAddressLine1	60 Binney Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	City Area Code CityAreaCode	339
	dei	Local Phone Number LocalPhoneNumber	499-9300
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	BLUE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	67578549	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	353468000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	317705000	USD
CY2021Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	486233000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	833546000	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	33726000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	37472000	USD
CY2021Q2	blue	Receivables And Other Current Assets ReceivablesAndOtherCurrentAssets	16597000	USD
CY2020Q4	blue	Receivables And Other Current Assets ReceivablesAndOtherCurrentAssets	16116000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	13502000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	10698000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	903526000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	1215537000	USD
CY2021Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	101927000	USD
CY2020Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	122891000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	158820000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	162831000	USD
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16263000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10041000	USD
CY2021Q2	us-gaap	Goodwill Goodwill	13128000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	13128000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	190993000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	184019000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	69802000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	72805000	USD
CY2021Q2	us-gaap	Assets Assets	1454459000	USD
CY2020Q4	us-gaap	Assets Assets	1781252000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	39294000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21602000	USD
CY2021Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	168035000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	145406000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	28669000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25024000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2687000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2320000	USD
CY2021Q2	blue	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	9080000	USD
CY2020Q4	blue	Collaboration Research Advancement Current CollaborationResearchAdvancementCurrent	9236000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	247765000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	203588000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25762000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	25762000	USD
CY2021Q2	blue	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	18547000	USD
CY2020Q4	blue	Collaboration Research Advancement Non Current CollaborationResearchAdvancementNonCurrent	21581000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	169933000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	167997000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7891000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	7268000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	469898000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	426196000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67551000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67551000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66432000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66432000	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	676000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	665000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4337719000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4260443000	USD
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5777000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5505000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3348057000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2900547000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	984561000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1355056000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1454459000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1781252000	USD
CY2021Q2	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	1670000	USD
CY2020Q2	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	109674000	USD
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	3190000	USD
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	111976000	USD
CY2021Q2	us-gaap	Revenues Revenues	7472000	USD
CY2020Q2	us-gaap	Revenues Revenues	198890000	USD
	us-gaap	Revenues Revenues	20267000	USD
	us-gaap	Revenues Revenues	220753000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	144315000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	156308000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	298793000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	310431000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	78576000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	68628000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	165451000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	141876000	USD
CY2021Q2	blue	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	-10071000	USD
CY2020Q2	blue	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	0	USD
	blue	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	-10071000	USD
	blue	Income Loss From Collaborative Arrangements IncomeLossFromCollaborativeArrangements	0	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15301000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1554000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17582000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2579000	USD
CY2021Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	47000	USD
CY2020Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-1655000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	416000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4763000	USD
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	248310000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	224835000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	492313000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	450123000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-240838000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-25945000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-472046000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-229370000	USD
CY2021Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	439000	USD
CY2020Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2939000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1149000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	8294000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1087000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1551000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	23669000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2896000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-241486000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21455000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-447228000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-223972000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	216000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	282000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	104000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-241702000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-21465000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-447510000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-224076000	USD
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.58
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.58
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.66
	blue	Interest Receivable Write Off InterestReceivableWriteOff	0	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.86
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.86
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67487000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67487000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60384000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60384000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	67233000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	67233000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57987000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57987000	shares
CY2021Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0.0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0.0	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-100000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-100000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-328000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	399000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-272000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-507000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-328000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	399000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-272000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-507000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-242030000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21066000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-447782000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-224583000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1355056000	USD
CY2021Q1	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1219000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1707000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36090000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12013000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	56000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-205808000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	1200333000	USD
CY2021Q2	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26222000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-328000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-241702000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	984561000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1284993000	USD
CY2020Q1	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	750000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1872000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36335000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-906000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-202611000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1120433000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	33465000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	541536000	USD
CY2020Q2	blue	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	0	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	347000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	40781000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	399000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-21465000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	1682031000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-447510000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-224076000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	416000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-4763000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11353000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9430000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	73687000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	84822000	USD
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	28286000	USD
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-3343000	USD
	blue	Inventory Excess Valuation Reserves InventoryExcessValuationReserves	15084000	USD
	blue	Inventory Excess Valuation Reserves InventoryExcessValuationReserves	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6228000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	1841000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13923000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9347000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	17404000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4466000	USD
	blue	Lessee Increase Decrease In Operating Lease Right Of Use Asset LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset	15074000	USD
	blue	Lessee Increase Decrease In Operating Lease Right Of Use Asset LesseeIncreaseDecreaseInOperatingLeaseRightOfUseAsset	11085000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7475000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-14042000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	20276000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-14025000	USD
	blue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-16468000	USD
	blue	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-10131000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	367000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11412000	USD
	blue	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	3190000	USD
	blue	Increase Decrease In Collaboration Research Advancement IncreaseDecreaseInCollaborationResearchAdvancement	3779000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-348975000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-166378000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9204000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15478000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	196145000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	101421000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	557751000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	580875000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	31318000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	29878000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	381720000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	493854000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	541536000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	4192000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2549000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4192000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	544085000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	36937000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	871561000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	373728000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	381709000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	410665000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1253270000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	353468000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1198768000	USD
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	2687000	USD
CY2020Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	USD
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	54510000	USD
CY2020Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	54502000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	410665000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1253270000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1508000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1257000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	22049000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14663000	USD
	us-gaap	Stock Issued1 StockIssued1	12013000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	Description of the business<div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bluebird bio, Inc. (the “Company” or “bluebird”) was incorporated in Delaware on April 16, 1992, and is headquartered in Cambridge, Massachusetts. The Company is a biotechnology company committed to researching, developing and commercializing, following marketing approval, potentially transformative gene therapies for severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide selling, general and administrative support for these operations, including commercial activities in Europe as well as commercial-readiness activities in the United States.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s programs in severe genetic diseases include programs for transfusion-dependent β-thalassemia, or TDT, sickle cell disease, or SCD, and cerebral adrenoleukodystrophy, or CALD. The Company’s programs in oncology are focused on developing novel engineered cell and gene therapies for cancer, including the anti-BCMA CAR T programs for multiple myeloma under the Company’s collaboration arrangement with Bristol-Myers Squibb ("BMS"). Please refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative arrangements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further discussion of the Company’s collaboration with BMS.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, BMS received marketing approval from the U.S. Food and Drug Administration for idecabtagene vicleucel (ide-cel, marketed as ABECMA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) as a treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. In July 2021, the Company received marketing approval from the European Commission for elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy) as a treatment for patients less than 18 years of age with early cerebral adrenoleukodystrophy and without a matched sibling donor. In June 2019, the Company received conditional marketing authorization from the European Commission for betibeglogene autotemcel (beti-cel; formerly LentiGlobin for β-thalassemia gene therapy) as a treatment of patients 12 years and older with TDT who do not have a β</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/β</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte-matched related HSC donor is not available. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced its intent to separate its severe genetic disease and oncology programs into two separate, independent publicly traded companies, bluebird bio, Inc. and 2seventy bio, Inc., a newly-formed Delaware corporation and wholly-owned subsidiary of the Company prior to the separation. bluebird bio, Inc. intends to retain focus on its severe genetic disease programs, with a focus on the U.S. market. As part of this strategy, bluebird bio, Inc. plans to execute an orderly wind down of its European operations. 2seventy bio, Inc. is expected to focus on the Company's oncology programs. The spin-off transaction is expected to be completed in late 2021 and is anticipated to be tax-free, subject to receipt of a favorable Internal Revenue Service (“IRS”) ruling. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company has incurred losses since inception and to date has financed its operations primarily through the sale of equity securities and, to a lesser extent, through collaboration agreements and grants from governmental agencies and charitable foundations. As of June 30, 2021, the Company had an accumulated deficit of $3.35 billion. During the six months ended June 30, 2021, the Company incurred a loss of $447.5 million and used $349.0 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of beti-cel, eli-cel, LentiGlobin for SCD, and its oncology product candidates, and the achievement of a level of revenues adequate to support its cost structure. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, the Company had cash, cash equivalents and marketable securities of $941.6 million. The Company expects its cash, cash equivalents and marketable securities will be sufficient to fund current planned operations for at least the next twelve months from the date of issuance of these financial statements, although it intends to pursue additional cash resources through public or private equity or debt financings or by establishing additional collaborations with other companies. Management's expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management's estimates, the Company may need to seek additional </span></div>strategic or financing opportunities sooner than would otherwise be expected. However, there is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research or development programs or be unable to expand its operations or commercialize products following marketing approval.
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3350000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-447500000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-349000000.0	USD
CY2021Q2	us-gaap	Investments And Cash InvestmentsAndCash	941600000	USD
	blue	Interest Receivable Write Off InterestReceivableWriteOff	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, and the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, revenue recognition, income taxes, inventory capitalization, excess inventory analyses, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements.</span></div>
CY2021Q2	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	4305000	USD
CY2021Q2	blue	Equity Securities Unrealized Gain EquitySecuritiesUnrealizedGain	0	USD
CY2021Q2	blue	Equity Securities Unrealized Loss EquitySecuritiesUnrealizedLoss	1685000	USD
CY2021Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2620000	USD
CY2021Q2	blue	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	589706000	USD
CY2021Q2	blue	Marketable Securities Unrealized Gains MarketableSecuritiesUnrealizedGains	179000	USD
CY2021Q2	blue	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	1725000	USD
CY2021Q2	us-gaap	Marketable Securities MarketableSecurities	588160000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	20017000	USD
CY2020Q4	blue	Equity Securities Unrealized Gain EquitySecuritiesUnrealizedGain	0	USD
CY2020Q4	blue	Equity Securities Unrealized Loss EquitySecuritiesUnrealizedLoss	14364000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5653000	USD
CY2020Q4	blue	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	970180000	USD
CY2020Q4	blue	Marketable Securities Unrealized Gains MarketableSecuritiesUnrealizedGains	735000	USD
CY2020Q4	blue	Marketable Securities Unrealized Loss MarketableSecuritiesUnrealizedLoss	14478000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	956437000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2021Q2	us-gaap	Interest Receivable InterestReceivable	1900000	USD
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	3100000	USD
CY2021Q2	blue	Interest Receivable Write Off InterestReceivableWriteOff	0	USD
CY2020Q2	blue	Interest Receivable Write Off InterestReceivableWriteOff	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	111117000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	40000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	111117000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	40000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	287982000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	114000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	1205000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	289187000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	114000	USD
CY2021Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	2600000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	5700000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	31300000	USD
CY2021Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	12290000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	8967000	USD
CY2021Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1212000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1731000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	13502000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	10698000	USD
	blue	Inventory Excess Valuation Reserves InventoryExcessValuationReserves	15100000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	217781000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	213891000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58961000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51060000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	158820000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	162831000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	71749000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	55802000	USD
CY2021Q2	blue	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	24186000	USD
CY2020Q4	blue	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	22571000	USD
CY2021Q2	blue	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	19865000	USD
CY2020Q4	blue	Accrued Clinical And Contract Research Organization Costs Current AccruedClinicalAndContractResearchOrganizationCostsCurrent	23766000	USD
CY2021Q2	blue	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	20974000	USD
CY2020Q4	blue	Accrued Collaboration Research Costs Current AccruedCollaborationResearchCostsCurrent	20004000	USD
CY2021Q2	blue	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	1201000	USD
CY2020Q4	blue	Accrued Property Plant And Equipment Current AccruedPropertyPlantAndEquipmentCurrent	789000	USD
CY2021Q2	blue	Accrued License And Milestone Fees AccruedLicenseAndMilestoneFees	183000	USD
CY2020Q4	blue	Accrued License And Milestone Fees AccruedLicenseAndMilestoneFees	278000	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1982000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1541000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	27895000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20655000	USD
CY2021Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	168035000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	145406000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	2700000	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod	2200000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3900000	shares
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31100000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73500000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84800000	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31051000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48529000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73525000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84822000	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31051000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48529000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73525000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	73525000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84822000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84822000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	100000	USD
CY2021Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	400000	USD
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	193900000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6262000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	105.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	811000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	29.52
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	209000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.02
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	765000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	108.51
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6099000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	97.93
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3854000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	110.83
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6099000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	97.93
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	200000	shares
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1300000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8710000	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8710000	shares
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8382000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8382000	shares

Files In Submission

Name	View Source	Status
0001293971-21-000065-index-headers.html	Edgar Link	pending
0001293971-21-000065-index.html	Edgar Link	pending
0001293971-21-000065.txt	Edgar Link	pending
0001293971-21-000065-xbrl.zip	Edgar Link	pending
blue-20210630.htm	Edgar Link	pending
blue-20210630.xsd	Edgar Link	pending
blue-20210630xex1017.htm	Edgar Link	pending
blue-20210630xex1021.htm	Edgar Link	pending
blue-20210630xex1023.htm	Edgar Link	pending
blue-20210630xex311.htm	Edgar Link	pending
blue-20210630xex312.htm	Edgar Link	pending
blue-20210630xex321.htm	Edgar Link	pending
blue-20210630_cal.xml	Edgar Link	unprocessable
blue-20210630_def.xml	Edgar Link	unprocessable
blue-20210630_htm.xml	Edgar Link	completed
blue-20210630_lab.xml	Edgar Link	unprocessable
blue-20210630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BLUE
bluebird bio, Inc. Stock $blue

2021 Q2 Form 10-Q Financial Statement

#000129397121000065 Filed on August 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLUE bluebird bio, Inc. Stock $blue

2021 Q2 Form 10-Q Financial Statement

#000129397121000065 Filed on August 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BLUE
bluebird bio, Inc. Stock $blue